FDA Gets Mylan Suit Over Generic Lipitor Tossed

Law360, New York (May 2, 2011, 9:03 PM EDT) -- A federal judge in Washington on Monday tossed Mylan Pharmaceuticals Inc.'s suit to compel the U.S. Food and Drug Administration to weigh in on Ranbaxy Laboratories Ltd.'s exclusivity provision for marketing a generic version of Lipitor.

Mylan, which filed its own application with the FDA to market a Lipitor generic known as atorvastatin, has no standing to push the agency to act on a competitor's application, U.S. District Judge James E. Boasberg said in his opinion.

The FDA's decision could be lucrative to the company that...
To view the full article, register now.